beta-Alanine Concept

subject area of

• 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation  Academic Article
• A Benefit-Risk Assessment of Dabigatran in the Prevention of Venous Thromboembolism in Orthopaedic Surgery  Academic Article
• Activated prothrombin complex concentrate for dabigatran-associated bleeding  Academic Article
• Acute management of bleeding in patients on novel oral anticoagulants  Academic Article
• Additional Events in the RE-LY Trial  Academic Article
• Adherence to anticoagulant treatment with dabigatran in a real-world setting  Academic Article
• Advances in treatment and management  Academic Article
• Advantages and limitations of the new anticoagulants  Academic Article
• Analysis of Upper Gastrointestinal Adverse Events Among Patients Given Dabigatran in the RE-LY Trial  Academic Article
• Anticoagulation for the initial treatment of venous thromboembolism in people with cancer  Academic Article
• Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer  Academic Article
• Antithrombotic Therapy for Atrial Fibrillation  Academic Article
• Approach to the new oral anticoagulants in family practice: part 1: comparing the options.  Academic Article
• Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.  Academic Article
• Assessing the impact of dabigatran and warfarin on health-related quality of life: Results from an RE-LY sub-study  Academic Article
• Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation  Academic Article
• Bleeding and antidotes in new oral anticoagulants  Academic Article
• Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter  Academic Article
• Carnosine, taurine and enzyme activities of human skeletal muscle fibres from elderly subjects with osteoarthritis and young moderately active subjects  Academic Article
• Causes of Death and Influencing Factors in Patients With Atrial Fibrillation  Academic Article
• Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications  Academic Article
• Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation  Academic Article
• Dabigatran Versus Warfarin in Patients With Atrial Fibrillation  Academic Article
• Dabigatran and risk of myocardial infarction  Academic Article
• Dabigatran as anticoagulant therapy for atrial fibrillation. Which patients should receive it, which patients may not need it, and other practical aspects of patient management  Academic Article
• Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?  Academic Article
• Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial  Academic Article
• Dabigatran efficacy-safety assessment for stroke prevention in patients with atrial fibrillation  Academic Article
• Dabigatran for patients with a mechanical valve  Academic Article
• Dabigatran in Patients with Mechanical Heart Valves  Academic Article
• Dabigatran monitoring made simple?  Academic Article
• Dabigatran versus Warfarin in Patients with Mechanical Heart Valves  Academic Article
• Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada  Academic Article
• Dabigatran versus warfarin in patients with mechanical heart valves: reply  Academic Article
• Dabigatran-Induced Acute Hepatitis  Academic Article
• Dabigatran-related coagulopathy: when can we assume the effect has “worn off”?  Academic Article
• Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation  Academic Article
• Efficacy and Safety of Dabigatran Compared to Warfarin in Patients With Paroxysmal, Persistent, and Permanent Atrial Fibrillation  Academic Article
• Efficacy and Safety of Dabigatran vs. Warfarin in Patients With Atrial Fibrillation - Sub-Analysis in Japanese Population in RE-LY Trial -  Academic Article
• Enoxaparin Versus Dabigatran or Rivaroxaban for Thromboprophylaxis After Hip or Knee Arthroplasty  Academic Article
• Evolving use of new oral anticoagulants for treatment of venous thromboembolism  Academic Article
• Extended Anticoagulation in Venous Thromboembolism  Academic Article
• Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism  Academic Article
• Extended anticoagulation in venous thromboembolism.  Academic Article
• Extended anticoagulation in venous thromboembolism.  Academic Article
• Extended anticoagulation in venous thromboembolism.  Academic Article
• Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies  Academic Article
• Home-monitoring of oral anticoagulation vs. dabigatran  Academic Article
• How I treat target-specific oral anticoagulant–associated bleeding  Academic Article
• Idarucizumab for Dabigatran Reversal  Academic Article
• Intensity and Quality of Warfarin Anticoagulation in Chinese Patients  Academic Article
• Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran  Academic Article
• Is there a role for the novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials  Academic Article
• Is there really misuse and abuse of dabigatran?  Academic Article
• Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants  Academic Article
• Letter by Van de Werf et al Regarding Article, “Using Dabigatran in Patients With Stroke: A Practical Guide for Clinicians”  Academic Article
• Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin  Academic Article
• Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor  Academic Article
• Management of Anticoagulation Around Pacemaker and Defibrillator Surgery  Academic Article
• Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting  Academic Article
• More on Acutely Injured Patients Receiving Dabigatran  Academic Article
• Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial  Academic Article
• New anticoagulants in atrial fibrillation management  Conference Paper
• New oral anticoagulant agents – general features and outcomes in subsets of patients  Academic Article
• New oral anticoagulants and oculoplastic surgery  Academic Article
• New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions  Academic Article
• New oral anticoagulants: which one should my patient use?  Academic Article
• Novel oral anticoagulants in secondary prevention of stroke  Academic Article
• Nutritional Strategies to Support Adaptation to High-Intensity Interval Training in Team Sports  Academic Article
• Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits  Academic Article
• Overview of the New Oral Anticoagulants  Academic Article
• Patient outcomes using the European label for dabigatran  Academic Article
• Perioperative Management of Dabigatran  Academic Article
• Perioperative management of patients who are receiving a novel oral anticoagulant  Academic Article
• Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin  Academic Article
• Periprocedural Management and Approach to Bleeding in Patients Taking Dabigatran  Academic Article
• Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy  Academic Article
• Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran  Academic Article
• Pharmacologic Properties of the New Oral Anticoagulants: A Clinician-oriented Review with a Focus on Perioperative Management  Academic Article
• Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation  Academic Article
• Practical aspects of new oral anticoagulant use in atrial fibrillation  Academic Article
• Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban  Academic Article
• Preventing Cardioembolic Stroke in Atrial Fibrillation with Dabigatran  Academic Article
• Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding  Academic Article
• Response to Letter Regarding Article, “Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study”  Academic Article
• Response to Letter Regarding Article, “Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial Analysis”  Academic Article
• Response to Letter Regarding Article, “Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin”  Academic Article
• Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”.  Academic Article
• Response.  Academic Article
• Risk Stratification and Stroke Prevention Therapy Care Gaps in Canadian Atrial Fibrillation Patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation Chart Audit)  Academic Article
• Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation  Academic Article
• Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS_2 Score: A Subgroup Analysis of the RE-LY Trial  Academic Article
• Safety and Efficacy of Dabigatran Compared With Warfarin for Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-analysis  Academic Article
• Stroke Prevention in Atrial Fibrillation Patients With Chronic Kidney Disease  Academic Article
• The Effects of Beta-Alanine Supplementation on Performance: A Systematic Review of the Literature  Academic Article
• The King is Dead (Warfarin): Direct Thrombin and Factor Xa Inhibitors: The Next Diadochian War?  Academic Article
• The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study  Academic Article
• The Oral Thrombin Inhibitor Dabigatran: Strengths and Weaknesses  Academic Article
• Transition from apixaban to warfarin—addressing excess stroke, systemic embolism, and major bleeding  Academic Article
• Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis  Academic Article
• Treatment of venous thromboembolism with dabigatran  Academic Article
• Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation.  Academic Article
• Venous thromboembolism management: where do novel anticoagulants fit?  Academic Article
• Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin  Academic Article
• β-Alanine Supplementation Does Not Augment the Skeletal Muscle Adaptive Response to 6 Weeks of Sprint Interval Training  Academic Article
• γT -S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo  Academic Article